Estimating Long-Term Organ Damage Risk in Patients with Congenital Thrombotic Thrombocytopenic Purpura Receiving Recombinant ADAMTS13 Prophylaxis: A Structured Expert Elicitation Study
Open Access
- 9 October 2026
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- p. 1-16
Abstract
No abstract availableKeywords
Funding Information
- Takeda Development Center Americas, Inc., Lexington, MA, USA
This publication has 22 references indexed in Scilit:
- 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpuraJournal of Thrombosis and Haemostasis, 2025
- Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making: A Good Practices Report of an ISPOR Task ForceValue in Health, 2024
- Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 2024
- Long‐term follow‐up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma‐derived factor VIII (Koate) that contains ADAMTS13Haemophilia, 2023
- A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathiesBritish Journal of Haematology, 2023
- Reference Case Methods for Expert Elicitation in Health Care Decision MakingMedical Decision Making, 2021
- Current prophylactic plasma infusion protocols do not adequately prevent long‐term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohortBritish Journal of Haematology, 2021
- Thrombotic thrombocytopenic purpuraNature Reviews Disease Primers, 2017
- Von Willebrand Factor, ADAMTS13, and the Risk of MortalityArteriosclerosis, Thrombosis, and Vascular Biology, 2016
- ADAMTS13 content in plasma‐derived factor VIII/von Willebrand factor concentratesAmerican Journal of Hematology, 2013